Future developments in biosensors for field‐ready SARS‐CoV‐2 virus diagnostics

Fani, Mona; Zandi, Milad; Soltani, Saber; Abbasi, Samaneh

doi:10.1002/bab.2033

Cited by 37 publications

(34 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After SARS-CoV and the Middle East respiratory syndrome (MERS-CoV) in 2002 and 2012, SARS-CoV-2 is the third known zoonotic coronavirus in the past two decades. SARS-CoV, MERS-CoV and SARS-CoV-2 are the members of the β subgroup [ 4 ].…”

mentioning

confidence: 99%

The Role of miRNAs in COVID-19 Disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

Nowadays, the SARS Coronavirus 2 (SARS-CoV-2) infection is recognized as the primary cause of mortality in humans. SARS-CoV-2 is transmitted through human-to-human contact and is asymptomatic in most patients. In addition to approved vaccines against SARS-CoV-2 infection, miRNAs may also be promising options against this new virus. miRNAs are small and noncoding RNAs 18–25 nucleotides in length that target the mRNAs to degrade them or obstruct their translation miRNAs act as an observer in cells. This study reviewed the literature on the potential role of cellular miRNAs in the SARS-CoV-2-host interplay as a therapeutic option in COVID-19 patients.

show abstract

mentioning

confidence: 99%

The Role of miRNAs in COVID-19 Disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The primary transmission route of COVID-19 is respiratory droplets. It can also be transmitted through close contact [ 93 , 94 ]. Human microbiota comprises viruses, phages, bacteria, and fungi [ 95 ].…”

Section: Respiratory Microbiota and Covid-19mentioning

confidence: 99%

The Role of Bacterial and Fungal Human Respiratory Microbiota in COVID-19 Patients

Soltani

Zakeri

Zandi

et al. 2021

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Recently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19), has led to a worldwide pandemic with millions of infected patients. Alteration in humans’ microbiota was also reported in COVID-19 patients. The alteration in human microbiota may contribute to bacterial or viral infections and affect the immune system. Moreover, human’s microbiota can be altered due to SARS-CoV-2 infection, and these microbiota changes can indicate the progression of COVID-19. While current studies focus on the gut microbiota, it seems necessary to pay attention to the lung microbiota in COVID-19. This study is aimed at reviewing respiratory microbiota dysbiosis among COVID-19 patients to encourage further studies on the field for assessment of SARS-CoV-2 and respiratory microbiota interaction.

show abstract

“…50 Nano and biosensors should be technically developed for highly efficient detection of SARS-CoV-2 in various clinical samples, including urine, blood, saliva, and nasopharyngeal swabs. 50,60 One of the important limitations for developing biosensors based on biological reagents (such as antibody, DNA, and antigen) is time consuming and costly procedures of extraction and/or preparation of target biological metrics/reagents. 61 Thus, the designing of nanomaterials-enabled biosensors that do not need extra extraction procedures is highly needed.…”

Section: Challenges and Opportunitiesmentioning

confidence: 99%